Janus kinase

JAK2 is a member of the Janus kinase family.

IL2RG has been shown to interact with Janus kinase 3.

Ruxolitinib is a Janus kinase inhibitor with selectivity for subtypes 1 and 2 of this enzyme.

Treatment with an inhibitor of the Janus kinase (JAK).

Janus kinase 2 (commonly called JAK2) is a non-receptor tyrosine kinase.

Janus kinase 3 is a tyrosine kinase that belongs to the Janus family of kinases.

These receptors in turn rely on the Janus kinase (JAK) family of enzymes for signal transduction.

Interleukin 10 receptor, alpha subunit has been shown to interact with Interleukin 10 and Janus kinase 1.

Janus kinase 3 deficiency or JAK3 deficiency is a defect in the body's cytokine receptors and their signaling.

Emerging clinical research has demonstrated the integral role of Janus kinase (JAK) proteins in the pathogenesis of psoriasis.

Janus kinase, an intracellular signaling molecule; component of the JAK-STAT signal system.

Mutations that abrogate Janus kinase 3 function cause an autosomal SCID (severe combined immunodeficiency disease).

This results in the activation of Janus kinase 2, a tyrosine kinase that initiates the JAK-STAT pathway.

TG101348 (SAR302503) is an orally available inhibitor of Janus kinase 2 (JAK-2) developed for the treatment of patients with myeloproliferative diseases including myelofibrosis.

One such receptor-associated tyrosine kinase is Janus kinase (JAK), many of whose effects are mediated by STAT proteins.

The intracellular domain of type II cytokine receptors is typically associated with a tyrosine kinase belonging to the Janus kinase (JAK) family.

Upon dimerisation of the α and β subunits the β subunit becomes phosphorylated on tyrosine residues by members of the Janus kinase (JAK) family.

Signal transducing adaptor molecule has been shown to interact with STAMBP, HGS, TIMM8A and Janus kinase 2.

Janus kinase (JAK) is a family of intracellular, nonreceptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway.

Instead of carrying covalently associated tyrosine kinase domains, Jak-STAT receptors form noncovalent complexes with tyrosine kinases of the Jak (Janus kinase) class.

Growth hormone receptor has been shown to interact with SGTA, PTPN11, Janus kinase 2, Suppressor of cytokine signaling 1 and CISH.

The alpha chain does not participate in signaling, but the beta chain is complexed with an enzyme called Janus kinase 1 (JAK1), that is capable of adding phosphate groups to molecules.

Protein arginine methyltransferase 5 has been shown to interact with WD repeat-containing protein 77, CLNS1A, Janus kinase 2, SNRPD3 and SUPT5H.

It also has activity against cells expressing JAK2(V617F), a mutated form of the janus kinase 2 (JAK2) enzyme that is implicated in the pathophysiology of many myeloproliferative diseases, including polycythaemia vera.

SOCS3 has been shown to interact with PTPN11, Glycoprotein 130, Erythropoietin receptor, Janus kinase 2, RAS p21 protein activator 1 and Insulin-like growth factor 1 receptor.